LIPC Genotype

Two people can eat the same breakfast and end up with very different cholesterol numbers a few hours later. Part of that difference is written into your DNA, in a gene called LIPC (the hepatic lipase gene).

This test reads the specific letters of DNA at this gene to tell you which version you inherited. That single piece of information helps explain why your HDL runs high or low, why your LDL particles may be small and dense or large and fluffy, and how your body clears fat from your bloodstream after you eat.

What This Gene Actually Does

LIPC carries the instructions for hepatic lipase, an enzyme your liver makes and sends into the bloodstream. Hepatic lipase clips apart fats and phospholipids inside circulating particles, helping reshape HDL, LDL, and the leftover particles your body produces after a meal.

Common variants in the gene change how much of this enzyme your liver makes. Lower hepatic lipase activity tends to leave you with higher HDL cholesterol and more buoyant, larger LDL particles. Higher activity is associated with smaller, denser LDL and lower HDL2 cholesterol.

Promoter variants like -514C>T (rs1800588) and -250G>A (rs2070895) are the most studied. In one study, LIPC genotype accounted for roughly 20 to 32 percent of the differences in hepatic lipase activity between people, a substantial influence for a single locus. These two variants sit close together and tend to be inherited as a pair, so they largely tag the same underlying signal rather than acting as independent contributors. Either way, LIPC is one of the strongest single genetic influences on HDL metabolism.

Heart Disease Risk

The relationship between LIPC variants and heart disease is real but complicated. In US diabetic men, the CT or TT genotype of the -514 variant was associated with increased coronary heart disease risk, but only in those who were obese. Beyond that specific group, the picture is broader. A large meta-analysis and Mendelian randomization study linked the -514T allele, which lowers hepatic lipase activity, to higher cardiovascular risk across populations. The GENES study found the T allele was tied to increased coronary artery disease risk specifically in people with normal triglyceride levels. So the T allele is not simply a problem for obese diabetics, it appears to carry cardiovascular risk in other settings too.

In Mexicans, the same -514T allele raised HDL and appeared to indirectly reduce type 2 diabetes risk through that HDL increase, although the direct association with diabetes itself was only borderline statistically significant. The protective effect runs through HDL rather than acting on diabetes directly.

In people with type 1 diabetes, the -480C>T promoter variant has been linked to greater coronary artery calcification, a measurable buildup of calcified plaque in the heart arteries. A separate study of South Korean adults found that the rs17269397 AA genotype was associated with increased coronary artery disease risk, though this emerged from a gene-environment combinatorial analysis rather than as a standalone main effect.

Rare loss-of-function variants tell a different story. People carrying just one such variant show significantly higher total cholesterol, LDL, and triglycerides than non-carriers, suggesting these uncommon mutations affect lipids even when only one copy is present.

Reconciling the Mixed Signal

LIPC is not a clean good gene, bad gene story. The Rotterdam Study found that the HDL-raising -514T allele actually increased heart attack risk in men, and that increase persisted even after accounting for HDL levels. In other words, the variant raises HDL and raises cardiovascular risk at the same time, through mechanisms that do not run through HDL. That is arguably the most important nuance for interpreting any LIPC result: an HDL-raising variant is not automatically protective. Think of this gene as a phenotype shaper, not a verdict. It tells you which lipid pattern your body tends to produce, and that pattern carries different risks depending on your weight, blood sugar, and other lipid markers.

Hypertension and Diabetes Links

A meta-analysis found that carriers of the A allele at rs2070895 had a modestly increased risk of high blood pressure, with an odds ratio of about 1.20 and a borderline p-value. The related rs1800588 variant did not show the same association.

For type 2 diabetes, the picture depends on the population. The -514T allele has been linked to insulin resistance and diabetes in some cohorts, while in Mexicans the same allele appeared to indirectly reduce diabetes risk by raising HDL. In the HERITAGE Family Study, CC homozygotes at -514 showed the greatest improvements in insulin sensitivity with regular exercise training, suggesting the variant you carry may shape how strongly your body responds to lifestyle changes.

Eye Disease Associations

The HDL-raising T allele of rs10468017 is associated with a reduced risk of advanced age-related macular degeneration, a leading cause of vision loss in older adults. This finding came from a large genome-wide study and has been confirmed in meta-analysis.

In Chinese populations, LIPC variants rs10468017 and rs1532085 have been linked to polypoidal choroidal vasculopathy, a retinal disease that damages central vision. These findings should be read with caution: a comprehensive meta-analysis of polypoidal choroidal vasculopathy genetics found no overall significant association with LIPC, suggesting the Chinese findings may be population-specific rather than universal. Still, the broader pattern points to a real connection between HDL metabolism and the back of the eye that you would not see on any cholesterol panel.

Post-Meal Triglyceride Handling

A genome-wide study identified rs7350789 near LIPC as a determinant of how much your triglycerides rise after eating. People carrying the A allele had smaller spikes at 150 minutes after a meal, with effects concentrated in HDL-triglyceride and VLDL subparticles. This matters because the size and duration of post-meal triglyceride rises are increasingly recognized as independent contributors to long-term heart disease risk.

A One-Time Test, Used for a Lifetime

Your LIPC genotype does not change. The sequence of DNA at this gene was set at conception and will read the same whether you test today, in five years, or at age eighty. There is no value in repeating this test once you have a reliable result.

The ongoing value comes from what you do with it. If you carry a variant that lowers hepatic lipase activity, you can expect a tendency toward higher HDL and larger LDL particles, but you may still need to watch for elevated LDL particle counts and post-meal triglyceride spikes. If you carry a higher-activity variant, you may need to monitor HDL and LDL particle size more aggressively, especially if you carry extra weight or have insulin resistance. The companion tests that matter most are a standard lipid panel, ApoB, and an NMR lipoprotein particle analysis, and these should be repeated regularly throughout life.

What to Do With an Out-of-Pattern Result

A LIPC variant alone is not a diagnosis. It is one input into a fuller workup. If you carry a higher-risk variant and your standard lipid panel looks fine, that is not a green light. Add an ApoB measurement and an NMR lipoprotein particle test to see your actual LDL particle size and count. Post-meal lipid response testing is not part of standard clinical care, so the practical actions for most people with a common promoter variant are dietary, behavioral, and based on these widely available companion tests rather than specialty post-meal panels.

If you carry a rare loss-of-function variant and your LDL or triglycerides run high, a referral to a lipidologist is appropriate. Family members are likely to share the same variant, so close blood relatives should consider testing their own lipid panels. For the more common promoter variants, the action is usually behavioral: knowing your inherited tendency lets you choose dietary fat sources, exercise patterns, and monitoring frequency that match your biology.

When Results Can Be Misleading

• Variant panel coverage: this test detects specific LIPC variants the assay is designed to read. A result showing no risk variants does not rule out rarer mutations elsewhere in the gene that the panel does not cover.
• Population-specific effects: many LIPC associations were established in specific ethnic groups. A variant that raises diabetes risk in one population may appear protective in another, often because of differences in baseline HDL or body composition.
• Direct-to-consumer differences: results from clinical-grade genetic panels may differ from consumer ancestry-style reports, which use different methods and report different variants at the LIPC locus.
• Variants of uncertain significance: if your report flags a rare LIPC change not seen before, its meaning may be unknown. This is not the same as carrying a known disease variant.
• HDL-raising does not mean protective: some LIPC variants raise HDL but have still been linked to higher cardiovascular risk through mechanisms that do not run through HDL. A favorable-looking HDL number alongside a risk variant should not be read as reassurance.

What It Means to Carry a Variant

Carrying a LIPC risk variant does not guarantee you will develop heart disease, high blood pressure, or macular degeneration. These outcomes depend on your full genetic background, your weight, your other lipid markers, your blood pressure, and your behaviors. The variant raises or lowers probability. It does not set destiny. Use the result to know which lab numbers and lifestyle inputs to watch most closely, not to predict your future.